News

GENEVA, Switzerland, 14 April 2016 – Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90% disease control and 59% response rate in patients with malignant pleural mesothelioma (MPM), according to the results of a phase Ib trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1

DENVER – Patient advocates and advocacy organizations can now apply for the International Association for the Study of Lung Cancer (IASLC) Patient Advocacy Awards, which award free registration and travel expenses to up to five patient advocates for the IASLC 17th World Conference on Lung Cancer (WCLC) held December 4-7, 2016 in Vienna, Austria.

DENVER – Molecular analysis of a tumor biopsy from a proto-oncogene 1 receptor tyrosine kinase positive (ROS1+) patient with acquired crizotinib resistance revealed a novel mutation in the v-kit Hardy Zuckerman 4 feline sarcoma viral oncogene homolog receptor tyrosine kinase (KIT) that can potentially be targeted by KIT inhibitors.

GENEVA - The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have announced the 2016 Heine H. Hansen (HHH) Award recipient as Suresh Senan from Amsterdam. The award will be presented at the European Lung Cancer Conference (ELCC) 2016, held 13 to 16 April in Geneva, Switzerland.

April 2016 Newsletter

How can the IASLC make the biggest impact on improving the quantity and quality of life of thoracic cancer patients across the world?

DENVER – The International Association for the Study of Lung Cancer (IASLC) recently launched a program to provide free membership for patients/survivors of any thoracic malignancy.

Pages